Published in Jpn J Pharmacol on April 01, 1992
Dynorphin, stress, and depression. Brain Res (2009) 2.45
Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology (2006) 1.81
Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl) (2005) 1.43
kappa-Opioid receptor signaling and brain reward function. Brain Res Rev (2009) 1.32
Inhibition of kappa opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine. Psychopharmacology (Berl) (2009) 1.32
Endogenous kappa-opioid mediation of stress-induced potentiation of ethanol-conditioned place preference and self-administration. Psychopharmacology (Berl) (2010) 1.26
Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology (Berl) (2004) 1.21
Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys. Psychopharmacology (Berl) (2004) 1.20
Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement. Psychopharmacology (Berl) (2007) 1.04
Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology (Berl) (2004) 1.04
Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans. Biol Psychiatry (2012) 1.04
A neuropeptide-centric view of psychostimulant addiction. Br J Pharmacol (2008) 0.97
Social and environmental influences on opioid sensitivity in rats: importance of an opioid's relative efficacy at the mu-receptor. Psychopharmacology (Berl) (2005) 0.96
The role of kappa-opioid receptor activation in mediating antinociception and addiction. Acta Pharmacol Sin (2010) 0.95
Blockade of ethanol reward by the kappa opioid receptor agonist U50,488H. Alcohol (2009) 0.94
Evidence for habitual and goal-directed behavior following devaluation of cocaine: a multifaceted interpretation of relapse. PLoS One (2009) 0.93
A role for mu opioid receptors in cocaine-induced activity, sensitization, and reward in the rat. Psychopharmacology (Berl) (2007) 0.91
Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior. J Pharmacol Exp Ther (2009) 0.90
Pharmacologic dissociation between impulsivity and alcohol drinking in high alcohol preferring mice. Alcohol Clin Exp Res (2010) 0.87
The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior. J Nat Prod (2013) 0.86
Activation of κ opioid receptors increases intrinsic excitability of dentate gyrus granule cells. J Physiol (2011) 0.83
Novel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies. Expert Opin Drug Discov (2014) 0.82
Interactions between opioids and cocaine on locomotor activity in rats: influence of an opioid's relative efficacy at the mu receptor. Psychopharmacology (Berl) (2003) 0.82
Acute withdrawal from chronic escalating-dose binge cocaine administration alters kappa opioid receptor stimulation of [35S] guanosine 5'-O-[gamma-thio]triphosphate acid binding in the rat ventral tegmental area. Neuroscience (2010) 0.82
Kappa Opioid Receptor-Mediated Disruption of Novel Object Recognition: Relevance for Psychostimulant Treatment. J Addict Res Ther (2011) 0.79
Effects of ATPM-ET, a novel κ agonist with partial μ activity, on physical dependence and behavior sensitization in mice. Acta Pharmacol Sin (2010) 0.79
Persistent increases in rat hypothalamic POMC gene expression following chronic withdrawal from chronic "binge" pattern escalating-dose, but not steady-dose, cocaine. Neuroscience (2015) 0.78
Pharmacological modulation of neuropathic pain-related depression of behavior: effects of morphine, ketoprofen, bupropion and [INCREMENT]9-tetrahydrocannabinol on formalin-induced depression of intracranial self-stimulation in rats. Behav Pharmacol (2016) 0.77
Cocaine place conditioning increases pro-opiomelanocortin gene expression in rat hypothalamus. Neurosci Lett (2012) 0.77
[The endogenous opioid system and drug addiction]. Ann Pharm Fr (2010) 0.76
The opioid receptors as targets for drug abuse medication. Br J Pharmacol (2015) 0.75
Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta (2000) 5.39
Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet (1992) 5.14
Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. Proc Natl Acad Sci U S A (1992) 4.13
Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science (1999) 3.22
Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem (1999) 3.06
A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J Biol Chem (1986) 2.65
ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature (1991) 2.60
TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem (2001) 2.58
Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem (1992) 2.43
Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem (1999) 2.33
Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature (1997) 2.17
Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem (1990) 2.13
Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry (1990) 2.06
The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Res (1998) 1.94
Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol (1998) 1.90
Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology (1998) 1.75
Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab Invest (1992) 1.74
Degradation of chromosomal DNA during apoptosis. Cell Death Differ (2003) 1.73
Immunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): correlation with rheumatoid arthritis. Ann Rheum Dis (1989) 1.71
Degradation of interleukin 1beta by matrix metalloproteinases. J Biol Chem (1996) 1.69
Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res (1992) 1.55
The complete primary structure of human matrix metalloproteinase-3. Identity with stromelysin. J Biol Chem (1988) 1.54
Human plasma kallikrein. A rapid purification method with high yield. Biochem J (1981) 1.53
Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther (1992) 1.51
Detection of 12 germ-line mutations in the adenomatous polyposis coli gene by polymerase chain reaction. Gastroenterology (1993) 1.49
The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. Cancer Res (1992) 1.47
Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem (1997) 1.45
Structural properties of matrix metalloproteinases. Cell Mol Life Sci (1999) 1.43
Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. J Clin Invest (1989) 1.42
Purification of an endogenous activator of procollagenase from rabbit synovial fibroblast culture medium. J Biol Chem (1983) 1.42
Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem (1995) 1.42
Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases. FEBS Lett (1988) 1.39
Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J Immunol (1999) 1.38
Retroperitoneal haematoma due to ruptured microaneurysm of the pancreaticoduodenal artery. J Gastroenterol Hepatol (1993) 1.37
Hydrolysis of triple-helical collagen peptide models by matrix metalloproteinases. J Biol Chem (2000) 1.35
Enzymatic synthesis of D(-)-alpha-aminobenzylpenicillin by Kluyvera citrophila. J Antibiot (Tokyo) (1971) 1.33
Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res (1998) 1.33
Identification of the (183)RWTNNFREY(191) region as a critical segment of matrix metalloproteinase 1 for the expression of collagenolytic activity. J Biol Chem (2000) 1.32
Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem (1994) 1.32
The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts. Purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate. Biochem J (1988) 1.30
Single- versus bi-socket anterior cruciate ligament reconstruction using autogenous multiple-stranded hamstring tendons with endoButton femoral fixation: A prospective study. Arthroscopy (2001) 1.29
An improved assay for proteases and polysaccharidases employing a cartilage proteoglycan substrate entrapped in polyacrylamide particles. Anal Biochem (1980) 1.29
Augmented acetylcholine-induced, Rho-mediated Ca2+ sensitization of bronchial smooth muscle contraction in antigen-induced airway hyperresponsive rats. Br J Pharmacol (1999) 1.28
Continuously recording fluorescent assays optimized for five human matrix metalloproteinases. Anal Biochem (1991) 1.28
Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. Biochem J (1992) 1.27
Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists. J Med Chem (1988) 1.25
Evidence that human rheumatoid synovial matrix metalloproteinase 3 is an endogenous activator of procollagenase. Arch Biochem Biophys (1988) 1.24
Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int (1997) 1.23
Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. Arterioscler Thromb (1994) 1.23
A precursor form of latent collagenase produced in a cell-free system with mRNA from rabbit synovial cells. J Biol Chem (1981) 1.22
A novel host/tumor cell interaction activates matrix metalloproteinase 1 and mediates invasion through type I collagen. J Biol Chem (1999) 1.22
Recognition and catabolism of synthetic heterotrimeric collagen peptides by matrix metalloproteinases. Chem Biol (2000) 1.21
Biosynthesis and secretion of procollagenase by rabbit synovial fibroblasts. Inhibition of procollagenase secretion by monensin and evidence for glycosylation of procollagenase. Biochem J (1983) 1.21
Preferential inactivation of tissue inhibitor of metalloproteinases-1 that is bound to the precursor of matrix metalloproteinase 9 (progelatinase B) by human neutrophil elastase. J Biol Chem (1995) 1.20
Purification of the neutral proteoglycan-degrading metalloproteinase from human articular cartilage tissue and its identification as stromelysin matrix metalloproteinase-3. Biochem J (1989) 1.20
Opioid-induced second window of cardioprotection: potential role of mitochondrial KATP channels. Circ Res (1999) 1.20
Progressive polyarthritis induced in BALB/c mice by aggrecan from normal and osteoarthritic human cartilage. Arthritis Rheum (1998) 1.19
Kinetic analysis of matrix metalloproteinase activity using fluorogenic triple-helical substrates. Biochemistry (2001) 1.19
Cancer resistance genes in mice: models for the study of tumour modifiers. Trends Genet (1998) 1.19
Insights into MMP-TIMP interactions. Ann N Y Acad Sci (1999) 1.18
Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the mouse uterus during the peri-implantation period. Dev Genet (1997) 1.18
Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface. J Biol Chem (1998) 1.17
Folding and characterization of the amino-terminal domain of human tissue inhibitor of metalloproteinases-1 (TIMP-1) expressed at high yield in E. coli. FEBS Lett (1996) 1.16
Genetic diagnosis identifies occult lymph node metastases undetectable by the histopathological method. Cancer Res (1994) 1.16
Prognosis of unresectable hepatocellular carcinoma: an evaluation based on multivariate analysis of 90 cases. Hepatology (1991) 1.15
Co-culture of human breast adenocarcinoma MCF-7 cells and human dermal fibroblasts enhances the production of matrix metalloproteinases 1, 2 and 3 in fibroblasts. Br J Cancer (1995) 1.14
Steps involved in activation of the complex of pro-matrix metalloproteinase 2 (progelatinase A) and tissue inhibitor of metalloproteinases (TIMP)-2 by 4-aminophenylmercuric acetate. Biochem J (1995) 1.14
Siderochrome production by Yersinia pestis and its relation to virulence. Infect Immun (1975) 1.13
Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factor. Atherosclerosis (1991) 1.13
The mitogen-activated protein kinase and JAK-STAT signaling pathways are required for an oncostatin M-responsive element-mediated activation of matrix metalloproteinase 1 gene expression. J Biol Chem (1997) 1.13
Identification of plasma kallikrein as an activator of latent collagenase in rheumatoid synovial fluid. Biochim Biophys Acta (1982) 1.13
Opioid-induced cardioprotection against myocardial infarction and arrhythmias: mitochondrial versus sarcolemmal ATP-sensitive potassium channels. J Pharmacol Exp Ther (2000) 1.11
Mutational study of the amino-terminal domain of human tissue inhibitor of metalloproteinases 1 (TIMP-1) locates an inhibitory region for matrix metalloproteinases. J Biol Chem (1997) 1.08
Chemokines induce eosinophil degranulation through CCR-3. J Allergy Clin Immunol (2000) 1.08
Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin Exp Immunol (2002) 1.08
Human breast carcinoma cells cultured in the presence of serum shed membrane vesicles rich in gelatinolytic activities. J Submicrosc Cytol Pathol (1994) 1.08
Alternative splicing of the NF2 gene and its mutation analysis of breast and colorectal cancers. Hum Mol Genet (1994) 1.07
Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases. FEBS Lett (1999) 1.07
Activation of proMMP-9 by a plasmin/MMP-3 cascade in a tumor cell model. Regulation by tissue inhibitors of metalloproteinases. Ann N Y Acad Sci (1999) 1.06
Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog Growth Factor Res (1995) 1.05
Multiple forms of the APC gene transcripts and their tissue-specific expression. Hum Mol Genet (1993) 1.05
Norbinaltorphimine, a selective kappa-opioid receptor antagonist, induces an itch-associated response in mice. Eur J Pharmacol (2001) 1.05
Characterization of an immunosuppressive factor derived from colon cancer cells. J Immunol (1987) 1.04
Increased level of translatable collagenase messenger ribonucleic acid in rabbit synovial fibroblasts treated with phorbol myristate acetate or crystals of monosodium urate monohydrate. Biochemistry (1982) 1.04
Mecamylamine-precipitated nicotine-withdrawal aversion in rats. Eur J Pharmacol (1996) 1.04
Epithelial carcinogenesis in the mouse: correlating the genetics and the biology. Philos Trans R Soc Lond B Biol Sci (1998) 1.03
Early activation signal transduction pathways of Th1 and Th2 cell clones stimulated with anti-CD3. Roles of protein tyrosine kinases in the signal for IL-2 and IL-4 production. J Immunol (1995) 1.03
A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Ther (2010) 1.03
Salmonella virchow infection in an infant transmitted by household dogs. J Vet Med Sci (2000) 1.03
Differential expression of gelatinase B (MMP-9) and stromelysin-1 (MMP-3) by rheumatoid synovial cells in vitro and in vivo. Rheumatol Int (1993) 1.02
Only one pharmacophore is required for the kappa opioid antagonist selectivity of norbinaltorphimine. J Med Chem (1988) 1.02
A novel hydra matrix metalloproteinase (HMMP) functions in extracellular matrix degradation, morphogenesis and the maintenance of differentiated cells in the foot process. Development (2000) 1.02
Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1' residue of substrate. J Biol Chem (1999) 1.02
Matrix metalloproteinases and their inhibitors in human vitreous. Invest Ophthalmol Vis Sci (1998) 1.02
Importance of matrix metalloproteinases in human trophoblast invasion. Early Pregnancy (1995) 1.02
Induction of interleukin-12 p40 transcript by CD40 ligation via activation of nuclear factor-kappaB. Eur J Immunol (1997) 1.02
Expression of human pro-matrix metalloproteinase 3 that lacks the N-terminal 34 residues in Escherichia coli: autoactivation and interaction with tissue inhibitor of metalloproteinase 1 (TIMP-1). Biol Chem (1998) 1.01
Production of matrix metalloproteinases 2 and 3 (stromelysin) by stromal cells of giant cell tumor of bone. Am J Pathol (1992) 1.00